Glimerid (Glimepiride)

Glimerid (glimepiride) is indicated for the oral management of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient.

• Improves glycemic control as part of a comprehensive diabetes treatment plan.
• Can be combined with metformin or other oral antidiabetic agents when monotherapy is inadequate.
• May be used in patients with mild to moderate renal impairment, with dose adjustment as needed.
• Helps reduce fasting and post‑prandial blood glucose levels.
• Provides an option for patients who prefer a once‑daily oral regimen.

Like other sulfonylureas, glimepiride may cause a range of adverse effects that vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are skipped or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Skin rash or mild itching.

Serious

• Severe hypoglycemia leading to confusion, loss of consciousness, or seizures.
• Allergic reactions such as angioedema or Stevens‑Johnson syndrome.
• Hepatic dysfunction presenting as jaundice or elevated liver enzymes.
• Hematologic abnormalities like leukopenia or thrombocytopenia.

Healthcare providers should evaluate several factors before prescribing Glimerid to ensure safe and effective use.

• Assess renal and hepatic function; dose may need adjustment in impairment.
• Review patient history for prior sulfonylurea hypersensitivity or severe hypoglycemia.
• Caution in elderly patients due to increased risk of low blood sugar.
• Advise patients to maintain consistent meal patterns to avoid hypoglycemia.
• Monitor blood glucose regularly, especially during therapy initiation or dose changes.
• Consider pregnancy and lactation status; safety data are limited.
• Avoid use in patients with known sulfonylurea receptor mutations.

Glimepiride can interact with other medicines, affecting its glucose‑lowering action or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may impair glucose tolerance.
• Corticosteroids, which can increase blood glucose and require dose adjustments.
• Alcohol, which can enhance hypoglycemia risk, especially when consumed with meals.